AstraZeneca PLC Ordinary Shares (AZN) Analyst Ratings & Price Targets

AstraZeneca PLC Ordinary Shares

AZN · NYSE

Analyst Consensus

Buy

12 analysts

$162

Current

—

Low

$214

Average

—

High

Average target implies +32.20% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 12 analysts, with a mean target of $213.5; the consensus low and high were not available. Other aggregators place the average near $213.98 at TipRanks, $224.49 at Financhill and $235.52 at ChartMill, while Investing.com reports a much wider range of £11,300.39 to £19,986.50. No named analyst is identified as the most bullish; HSBC’s Rajesh Kumar is the least bullish identified after downgrading AstraZeneca to Hold from Buy. The only explicit weekly rating direction is negative, and no weekly target revisions were supplied. The substantive disagreement centers on strategic deal upside versus regulatory and integration risks.

Rating Actions

No individual rating actions have been captured for AZNyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

AstraZeneca And Bristol Myers Reportedly In Talks On $400 Bln DealRTTNews
Uncertain

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BMO CAPITAL MKT

DEUTSCHE BK SEC

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

TD COWEN

UBS

ZACKS RESEARCH

Symbol: AZN
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: NYSE

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.

Key Issues

Bullish view

A reported $400 billion combination with Bristol Myers Squibb could expand AstraZeneca’s pharmaceutical portfolio and strengthen its competitive position across major therapeutic areas.

Bearish view

The scale of the reported transaction could create substantial execution, financing, regulatory and integration risks, potentially destroying value even if the strategic rationale is sound.

Analyst Consensus

See all

Buy